7月31日，诺和诺德盘前跌超9%，报46.92美元。
消息面上，诺和诺德公布ZILTIVEKIMAB（白介素-6抑制剂）ZEUS三期临床试验结果，该药物未能显著降低动脉粥样硬化性心血管疾病、慢性肾病及炎症患者的主要不良心血管事件风险，未达到试验主要终点。公司表示，试验中ZILTIVEKIMAB组与安慰剂组整体安全性表现相近，后续仍将继续推进该药物在心力衰竭及急性心梗恢复期患者中的相关研究。
7月31日，诺和诺德盘前跌超9%，报46.92美元。
消息面上，诺和诺德公布ZILTIVEKIMAB（白介素-6抑制剂）ZEUS三期临床试验结果，该药物未能显著降低动脉粥样硬化性心血管疾病、慢性肾病及炎症患者的主要不良心血管事件风险，未达到试验主要终点。公司表示，试验中ZILTIVEKIMAB组与安慰剂组整体安全性表现相近，后续仍将继续推进该药物在心力衰竭及急性心梗恢复期患者中的相关研究。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.